Literature DB >> 23423463

t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.

Zhongling Zhang1, Xuhui Chen, Le Li, Keling Zhang, Shuqing Tian, Hongmei Gao, Hulun Li.   

Abstract

Cerebral ischemic stroke is one of the most prevalent diseases in senior individuals. Its therapeutical strategies include anticoagulation, thrombolysis and cell protection. Tissue-type plasminogen activator (t-PA) that interacts with thrombin for the lysis of thrombosis is widely used to treat stroke patients in early stage. The mechanism of action of t-PA is not clear. Here, we report a novel role of t-PA in protecting blood-brain barrier and its potential mechanisms. In a model of the blood-brain barrier with human umbilical vascular epithelium cells, we found that t-PA in low concentrations prevented the impairment of the blood-brain barrier as a result of oxygen and glucose deprivation. This protection was fulfilled by strengthening the junctions among vascular endothelia and by upregulating the productions of vascular endothelium growth factor and of zonula occludens-1. Therefore, t-PA may strengthen the junctions of vascular endothelia in the blood-brain barrier to improve the microenvironment of brain cells and, in turn, the outcome of stroke patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23423463     DOI: 10.1007/s10072-013-1293-0

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  27 in total

1.  LRP: a bright beacon at the blood-brain barrier.

Authors:  Joachim Herz
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 2.  Tissue plasminogen activator: beyond thrombolysis.

Authors:  Eduardo E Benarroch
Journal:  Neurology       Date:  2007-08-21       Impact factor: 9.910

3.  Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.

Authors:  Anne I Boullerne; Jose J Rodriguez; Tarik Touil; Bruno Brochet; Stephan Schmidt; Nora D Abrous; Michel Le Moal; Jeffrey R Pua; Mark A Jensen; Willy Mayo; Barry G W Arnason; Klaus G Petry
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

Review 4.  Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.

Authors:  John V Ly; Jorge A Zavala; Geoffrey A Donnan
Journal:  Expert Opin Pharmacother       Date:  2006-08       Impact factor: 3.889

5.  Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells.

Authors:  C Rosnoblet; U M Vischer; R D Gerard; J C Irminger; P A Halban; E K Kruithof
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-07       Impact factor: 8.311

6.  VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1.

Authors:  Samuel Valable; Joan Montaner; Anita Bellail; Vincent Berezowski; Julien Brillault; Romeo Cecchelli; Didier Divoux; Eric T Mackenzie; Myriam Bernaudin; Simon Roussel; Edwige Petit
Journal:  J Cereb Blood Flow Metab       Date:  2005-11       Impact factor: 6.200

Review 7.  Diagnosis and treatment of ischemic stroke.

Authors:  M J Alberts
Journal:  Am J Med       Date:  1999-02       Impact factor: 4.965

8.  Serial MRI after transient focal cerebral ischemia in rats: dynamics of tissue injury, blood-brain barrier damage, and edema formation.

Authors:  T Neumann-Haefelin; A Kastrup; A de Crespigny; M A Yenari; T Ringer; G H Sun; M E Moseley
Journal:  Stroke       Date:  2000-08       Impact factor: 7.914

9.  Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results.

Authors:  P Lyden; A Shuaib; K Ng; K Levin; R P Atkinson; A Rajput; L Wechsler; T Ashwood; L Claesson; T Odergren; E Salazar-Grueso
Journal:  Stroke       Date:  2002-01       Impact factor: 7.914

Review 10.  Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.

Authors:  Rao Muralikrishna Adibhatla; James F Hatcher
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.